News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Laura Cortesi

Articles by Laura Cortesi

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByPedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
April 22nd 2025

Trending on CancerNetwork

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

How KRAS-Targeted Therapy May Advance Toward Cancer Prevention

3D Visualization With da Vinci Single Port Boosts Breast Surgery Precision

Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer